View More Recent Stories
-
Roth/MKM Starts Replimune Group (REPL) at Buy
-
Replimune (REPL) Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
-
Replimune Group, Inc. (REPL) Tops Q1 EPS by 8c
-
Replimune (REPL) Announces $100 Million Private Placement Financing


